The Pharmaceutical Benefits Advisory Committee has supported a request to list cabozantinib on the PBS for the treatment of stage IV clear cell variant renal cell carcinoma. The positive PBAC recommendation from a December 2017 meeting was justified on a cost-minimisation basis against nivolumab. “The PBAC considered that cabozantinib had non-inferior efficacy compared to nivolumab ...
PBS listings supported for solid cancer drugs
By Mardi Chapman
16 Feb 2018